Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03766555 |
|
Recruitment Status :
Recruiting
First Posted : December 6, 2018
Last Update Posted : August 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Carcinoma, Hepatocellular | Procedure: Microwave ablation Procedure: Liver resection | Not Applicable |
Hepatocellular carcinoma (HCC) is a common cancer and is diagnosed at an earlier stage and with increasing frequency because of the wider implementation of screening programs. Whether liver resection or local ablation should be the first-line treatment in early HCC remains a hot topic for debate. Both are regarded as acceptable curative treatment for early HCC in many international guidelines. Underlying liver function is the key in treatment selection. The general consensus is that liver resection should be the treatment of choice in patients with good liver function while local ablation should be considered in patients with poor liver function. There exists a group of patients with apparently good liver function that harbor significant liver cirrhosis which is not easily picked up by the current assessment or scoring systems. Liver resection in this group of patients is burdened by potentially life-threatening complications and the overall survival is limited by their underlying liver cirrhosis. This is particularly important in early HCC as local ablation is another curative treatment option. In order to improve the prognosis of patients with early HCC, it is important to identify (1) patients with liver dysfunction to the extend that the risk of liver resection will outweigh the survival benefit it provides; (2) the best ablative method for HCC.
The investigators propose to carry out a prospective randomized controlled study to compare the treatment outcome of microwave ablation with liver resection in patients with borderline liver function whose HCC that are amendable to both liver resection and microwave ablation.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 76 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This is a prospective randomized study to be conducted in an academic hospital with a specialized hepato-biliary team. The principal investigator and other members within the team will perform patient selection and recruitment of this study according to the inclusion and exclusion criteria. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function |
| Actual Study Start Date : | May 21, 2018 |
| Estimated Primary Completion Date : | July 2023 |
| Estimated Study Completion Date : | July 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Microwave Ablation
Microwave ablation (MWA) will be performed in patients randomized to this arm.
|
Procedure: Microwave ablation
Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding. |
|
Active Comparator: Liver Resection
Liver resection will be performed in patients randomized to this arm.
|
Procedure: Liver resection
Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen. |
- Overall survival [ Time Frame: 5 years ]The primary outcome of this study is the overall survival
- Disease-free survival [ Time Frame: 5 years ]Disease-free survival
- Recurrence rate [ Time Frame: 5 years ]Liver cancer recurrence rate
- Morbidity rate [ Time Frame: 1 year ]Morbidity rate
- Hospital stay [ Time Frame: 1 year ]Hospital length of stay
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >18 years
- HCC amendable for both MWA and liver resection
- Liver function of ALBI Grade 2
- Tumour size </= 5cm
- Absence of extrahepatic metastasis
- Absence of radiology evidence of major vascular or bile duct invasion
Exclusion Criteria:
- Informed consent not available
- Patients with ALBI 3, Child-Pugh B or above
- Multifocal tumour
- Presence of portal vein or hepatic artery thrombosis
- Anticipation of concomitant procedures
- Emergency hepatectomy
- Ruptured HCC
- Patients with chronic renal failure
- Pregnant female patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03766555
| Contact: Chun Yeung, MSc | 35053933 | philipyeung@surgery.cuhk.edu.hk |
| Hong Kong | |
| Prince of Wales Hospital | Recruiting |
| Shatin, Hong Kong | |
| Contact: Charing CN Chong, MBChB | |
| Principal Investigator: | Charing CN Chong, MBChB | Chinese University of Hong Kong |
| Responsible Party: | Charing Chong, MD, Assistant Professor, Chinese University of Hong Kong |
| ClinicalTrials.gov Identifier: | NCT03766555 |
| Other Study ID Numbers: |
2016.205 |
| First Posted: | December 6, 2018 Key Record Dates |
| Last Update Posted: | August 4, 2021 |
| Last Verified: | August 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Hepatocellular carcinoma Hepatectomy Microwave Ablation Local Ablation |
|
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma |
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |